Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.

The data demonstrate statistically significant results in the primary endpoint of the study, 12-month event-free survival (EFS), where an event is defined as the recurrence of metastatic osteosarcoma, in OST-HER2-treated patients when compared with the published historical comparable control group.

Further, as of the most recent follow-up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival (‘OS,’ remaining alive) at the 1-year and 2-year interim time points of the ongoing 3-year overall survival secondary endpoint.

Notably, all patients who achieved the primary 12-month EFS endpoint remain alive.

“We are extremely pleased with these results of our Phase 2b clinical trial because they show that OST-HER2-treated patients achieved the primary endpoint of 12-month EFS in a statistically significantly higher ratio than comparable historical controls, in addition to increasing the likelihood of 1-year and 2-year survival as compared with comparable historical controls,” commented Robert Petit, Chief Medical & Scientific Officer of OS Therapies.

Primary Endpoint of 12-month EFS:

• 33% for OST-HER2 vs. 20% for historical control (p=0.0158)

Interim Analysis of Ongoing Secondary Endpoint, Overall Survival:

• 1-year: 91% for OST-HER2 vs. 80% for historical control (p=0.07) and 61% vs. 40% for 2-year (p = 0.0576).

Recently, OS Therapies closed a private placement financing, raising approximately $6 million in gross proceeds.

The company will use the proceeds for working capital, primarily on clinical and regulatory milestones, to support the commercialization of its lead therapeutic candidate, OST-HER2.

Price Action: OSTX stock is up 7.96% at $4.49 at last check Wednesday.

Read Next:

• Wells Fargo Q4 Earnings: Investors Cheer 50% Jump In Net Profit, ROE Improvement, Bank Expects Up To 3% Jump In 2025 NII

Photo via Shutterstock.